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Environmental Lead and Tobacco Smoke Exposure and Neurocognitive Performance in AttentionDeficit/Hyperactivity Disorder Jae-Won Choi, Jae-Won Kim Seoul National University Hospital, Republic of Korea Abstract Background: Previous studies have suggested that concentrations of lead in the blood and cotinine in the urine are associated with attention-deficit/hyperactivity disorder (ADHD) in youth. Lead is a heavy metal constituent contained in tobacco. Cotinine is a metabolite of nicotine, and it is used as a biomarker for exposure to tobacco smoke. However, only a few studies have analyzed what specific neurocognitive functions are associated with the concentrations of lead and cotinine in youth with ADHD. Methods: Ninety four youth diagnosed with ADHD and thirty controls (aged 5 to 18 years) participated in this study. A structured diagnostic interview (K-SADS-PL) was conducted with each participant of both groups for psychiatric diagnostic evaluation, and concentrations of blood lead and urinary cotinine were measured. All participants were assessed using the ADHD Rating Scale-IV (ADHD-RS), and they also took the continuous performance test (CPT) and the Stroop color-word test (SCWT). Multivariable linear regression model was used to evaluate associations of blood lead and urinary cotinine concentrations with the results of ADHD-RS, CPT, and SCWT; IQ, age, and gender were adjusted. Results: There was a significant difference in blood lead concentrations between the ADHD and control groups (1.5 ± 0.4 µg/dL vs. 1.2 ± 0.3 µg/dL, p=0.008). Blood lead concentrations showed a positive correlation with the CPT scores of omission errors (r=0.31, p<0.05) and response time variability (r=0.25, p<0.05). On the other hand, urinary cotinine concentrations did not demonstrate a meaningful correlation with any of the variables. In the multivariable linear regression model, blood lead concentrations were associated with CPT omission errors (B=0.274, p=0.009). Conclusions: Our results showed that high blood lead concentrations are associated with poor neurocognitive performance in ADHD, but urinary cotinine concentrations did not show any significant difference in between the ADHD and control groups and any association with the results of neurocognitive tests. Methods: In this 12-week randomized, double-blind, placebocontrolled cohort study with open-label, 12-week extension, subjects over 50 years of age, with AD defined by NINCDS-ADRDA criteria, and depression defined by Olin's provisional diagnostic criteria for depression of AD, were enrolled. The main outcome measure was the Cornell Scale for Depression in Dementia (CSDD), and various other measures of depression and cognition were repeated. Results: 91 subjects were screened, and 84 were randomized. (n = 42 for both groups). Twenty-four subjects (29%) were unable to finish the study, yielding a per protocol population of 60 subjects (study group: n = 27; placebo group: n = 33). At 12 weeks, mean CSDD scores were lower in the study group, and scores decreased faster, but the differences were not statistically significant. However, when subjects with 'definite major depression'
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